Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD

Next Previous
Trial Profile

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Bronchitis; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms M-34273-46
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 24 May 2017 Results of a post-hoc analysis assessing the efficacy of aclidinium bromide on cough-related endpoints in symptomatic patients with moderate COPD, stratified according to cough severity, presented at the 113th International Conference of the American Thoracic Society.
  • 24 May 2017 Primary endpoint has been met. (Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period), as reported in an abstract presented at the 113th International Conference of the American Thoracic Society
  • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top